GlassScriptPhysician profile
Jeremy P Holter
NPI 1003859778
$2,978.55
in general payments reported to CMS, 2019-2025
22 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.06 · 2022: $471 · 2023: $496 · 2024: $806 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,134.91 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $458.35 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $350.72 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $163.33 | 2024-2025 | |
| Amgen INC. | $130.67 | 2023-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.37 | 2025 | Caplyta |
| Corium, LLC | $99.07 | 2022-2024 | Azstarys |
| Sumitomo Pharma America, INC. | $68.21 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $67.86 | 2022-2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $58.38 | 2024-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $48.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.89 | 2022-2025 | Jardiance |
| Lundbeck LLC | $37.34 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $31.44 | 2021 | |
| Exact Sciences Corporation | $29.07 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26.75 | 2021-2025 | Wegovy, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $22.36 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $17.42 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $16.39 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.16 | 2021 | |
| Noven Therapeutics, LLC | $15.41 | 2025 | Xelstrym |
| Abbott Laboratories | $15.36 | 2024 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Holter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.